
Merck and DAIICHI SANKYO CO LTD withdrew their United States application seeking accelerated approval for an experimental lung cancer therapy. The decision marks the second setback under their $22B cancer partnership.
Merck and Daiichi Sankyo have withdrawn their US application for an experimental lung cancer therapy following discussions with regulators. The FDA determined that mid-stage trial data did not meet requirements for accelerated approval. The companies plan to continue evaluating the treatment in larger late-stage trials.

Merck and DAIICHI SANKYO CO LTD withdrew their United States application seeking accelerated approval for an experimental lung cancer therapy. The decision marks the second setback under their $22B cancer partnership.
Tudo o que você usa na web, mais rápido e no seu bolso.